# US 10,864,168 B2 · Bioactive delivery vehicles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,864,168 B2
- Document ID: US10864168B2
- Status: Granted
- Kind: B2
- Application number: 15/521,253
- Filed: 2015-10-28
- Published: 2018-10-18
- Granted: 2020-12-15
- Earliest claimed: 2014-10-29
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Nitin Nitin; Stephen Young; Jean Vandergheynst
- Web page: https://patentgrep.com/patent/US10864168B2

## CPC

- A61K 9/5089: {Processes}
- A23L 2/52: Adding ingredients (adding preservatives A23B70/10)
- A23L 27/72: {Encapsulation}
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A23L 33/14: Yeasts or derivatives thereof
- A23P 10/35: with oils, lipids, monoglycerides or diglycerides
- A61K 8/11: Encapsulated compositions
- A61K 8/9722: Chlorophycota or Chlorophyta [green algae], e.g. Chlorella
- A61K 8/9728: Fungi, e.g. yeasts
- A61K 8/9789: Magnoliopsida [dicotyledons]
- A61K 8/9794: Liliopsida [monocotyledons]
- A61K 8/99: from microorganisms other than algae or fungi, e.g. protozoa or bacteria
- A61K 9/5068: {Cell membranes or bacterial membranes enclosing drugs (liposomes with additional exogenous lipids A61K9/127)}
- A61K 31/07: Retinol compounds, e.g. vitamin A (retinoic acids A61K31/203)
- A61K 31/12: Ketones
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 35/20: Milk; Whey; Colostrum
- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 35/745: Bifidobacteria
- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61K 36/05: Chlorophycota or chlorophyta (green algae), e.g. Chlorella
- A61K 36/06: Fungi, e.g. yeasts
- A61K 36/064: Saccharomycetales, e.g. baker's yeast
- A61K 38/28: Insulins
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61Q 19/00: Preparations for care of the skin
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K 2035/11: {Medicinal preparations comprising living procariotic cells}
- A61K 2800/56: Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A23P: SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided are lipid membrane microcapsules encapsulating or containing bioactives, and methods of production and use.

## Claims

### Claim 1

A method of loading one or more bioactive agents into a lipid membrane microcapsule, comprising:
subjecting the lipid membrane microcapsule in the presence of the one or more bioactive agents to a vacuum pressure of at least about 25% of absolute vacuum levels for a period of 30 minutes or less;
wherein said bioactive agents enter an interior space of said microcapsule.

### Claim 2 (depends on 1)

The method of claim 1, wherein the lipid membrane microcapsule is subjected to the one or more bioactive agents in a solution selected from the group consisting of an aqueous solution and a non-aqueous solution.

### Claim 3 (depends on 1)

The method of claim 1, wherein said lipid membrane microcapsules are sealed in a container where the vacuum pressure (e.g., negative pressure) is in the range of at least about about 50% of absolute vacuum levels to at least about 99% absolute vacuum levels.

### Claim 4 (depends on 1)

The method of claim 1, further comprising, after subjecting the lipid membrane microcapsule to vacuum pressure, subjecting the lipid membrane microcapsule to positive external pressure.

### Claim 5 (depends on 1)

The method of claim 1, wherein the lipid membrane microcapsule is subjected to multiple iterations of vacuum pressure.

### Claim 6 (depends on 4)

The method of claim 4, wherein the lipid membrane microcapsule is subjected to multiple iterations of vacuum pressure and positive external pressure.

### Claim 7 (depends on 5)

The method of claim 5, wherein the bioactive lipid membrane microcapsule is subjected to additional bioactive between each iteration of vacuum pressure.

### Claim 8 (depends on 4)

The method of claim 4, wherein the lipid membrane microcapsule is subjected to positive external pressure for less than 10 minutes.

### Claim 9 (depends on 1)

The method of claim 1, wherein the lipid membrane microcapsule is a cell.

### Claim 10 (depends on 9)

The method of claim 9, wherein the cell comprises a cell wall.

### Claim 11 (depends on 10)

The method of claim 10, wherein the permeability of the cell or cell wall is modified.

### Claim 12 (depends on 1)

The method of claim 1, wherein the lipid membrane microcapsule is a subcellular organelle of a cell or is from a subcellular organelle of a cell.

### Claim 13 (depends on 1)

The method of claim 1, wherein the one or more bioactive agents are selected from the group consisting of a small organic compound, a peptide, a polypeptide, a polynucleotide, and a fatty acid.

### Claim 14 (depends on 13)

The method of claim 13, wherein the one or more bioactive agents have a molecular weight in the range of about 10 Da to about 30 kDa.

### Claim 15 (depends on 1)

The method of claim 1, wherein said one or more bioactive agent is selected from the group consisting of a hydrophobic bioactive, a hydrophilic bioactive, and a combination of at least one hydrophobic bioactive and at least one hydrophilic bioactive agent.

### Claim 16 (depends on 4)

The method of claim 4, wherein said positive external pressure is in the range of about 30 MPa to about 50 MPa.

### Claim 17 (depends on 16)

The method of claim 16, wherein the lipid membrane microcapsule is subjected to a vacuum pressure for less than 30 minutes and a positive external pressure for less than 90 minutes.

### Claim 18 (depends on 17)

The method of claim 17, wherein the lipid membrane microcapsule is subjected to iterations of vacuum pressure and positive external pressure in the range between 2 and 10 iterations.

### Claim 19 (depends on 17)

The method of claim 17, wherein the lipid membrane microcapsule is subjected to iterations of vacuum pressure of between about 3 Torr and about 10 Torr.